Safety, Tolerability, Pharmacokinetics and Food Effects Study of PBTZ169

NCT ID: NCT04150224

Last Updated: 2020-02-28

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-07-03
• Study Completion Date: 2019-02-01

Brief Summary

Open-label prospective non-comparative ascending dose randomized cohort study of single and multiple oral administration of PBTZ169 (capsules 80 mg) in healthy volunteers

Detailed Description

Open-label prospective non-comparativerandomized cohort study of safety, tolerability, pharmacokinetics and the effect of food of PBTZ169 in adult healthy volunteers after single and multiple oral administration. Study was conducted in one study center in the Russian Federation. The study included two stages:

Stage 1 - single or double oral administration with dose escalation (fasted/after meal) in 5 cohorts 10 healthy volunteers each plus 5 back-up volunteers;

Stage 2 - multiple oral administration once a day after meal for 14 days in 1 cohort of 10 healthy volunteers.

Conditions

Healthy Subjects

Keywords

PBTZ169; Macozinone; Antimycobacterial; Tuberculosis; Drug Resistant Tubercolosis; MDR-TB; XDR-TB

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

Cohort 1 (C1A), PBTZ169

Two doses of PBTZ169: 640 mg OD fasted and 640 mg OD after meal. Wash-out period ≥6 days.

Group Type: EXPERIMENTAL

PBTZ169 640 mg OD

Intervention Type: DRUG

Two administrations once a day with a wash-out period: food effect

Cohort 1 (C1B), PBTZ169

Two doses of PBTZ169: 640 mg OD after meal and 640 OD mg fasted. Wash-out period ≥6 days.

Group Type: EXPERIMENTAL

PBTZ169 640 mg OD

Intervention Type: DRUG

Two administrations once a day with a wash-out period: food effect

Cohort 2 (C2), PBTZ169

Single dose of PBTZ169: 960 mg fasted

Group Type: EXPERIMENTAL

PBTZ169 960 mg SD

Intervention Type: DRUG

Once a day fasted

Cohort 3 (C3), PBTZ169

Two doses of PBTZ169: 640 mg twice a day (fasted) with a 12-hour interval; total daily dose - 1280 mg

Group Type: EXPERIMENTAL

PBTZ169 640 mg BiD

Intervention Type: DRUG

Twice a day fasted; 1 day of administration

Cohort 4 (C4), PBTZ169

Single dose of PBTZ169: 1280 mg fasted

Group Type: EXPERIMENTAL

PBTZ169 1280 mg SD

Intervention Type: DRUG

Once a day fasted

Cohort 5 (C5), PBTZ169

Multiple administration of PBTZ169: 1280 mg once a day after meal for 14 days

Group Type: EXPERIMENTAL

PBTZ169 1280 mg MD

Intervention Type: DRUG

Once a day after meal, 14 doses

Interventions

PBTZ169 640 mg OD

Two administrations once a day with a wash-out period: food effect

Intervention Type: DRUG

PBTZ169 640 mg BiD

Twice a day fasted; 1 day of administration

Intervention Type: DRUG

PBTZ169 960 mg SD

Once a day fasted

Intervention Type: DRUG

PBTZ169 1280 mg SD

Once a day fasted

Intervention Type: DRUG

PBTZ169 1280 mg MD

Once a day after meal, 14 doses

Intervention Type: DRUG

Other Intervention Names

Macozinone (PBTZ169); Macozinone (PBTZ169); Macozinone (PBTZ169); Macozinone (PBTZ169); Macozinone (PBTZ169)

Eligibility Criteria

Inclusion Criteria

1. Written informed consent from the volunteer.

2. Men and women aged 18-45 years, inclusive.

3. Body mass index of 18.5-30 kg/m2.

4. Verified "healthy" diagnosis based on physical examination, vital signs, standard laboratory tests (complete blood count and biochemical blood test, urine analysis) and instrumental tests (ECG, fluorography examination or X-ray examination).

5. Negative results of tests for human immunodeficiency virus (HIV), syphilis, hepatitis B (Hbs Ag) and hepatitis C (antibodies to HCV).

6. Ability to comply with all the requirements of the protocol in the opinion of the investigator.

7. Consent of the participant and his/her partner to use reliable contraceptive methods during the study and within 90 days after the end of their participation. A reliable method of contraception is a combination of a male condom with at least one of the following methods:

• hormonal contraceptives used by the male's partner (only if she does not participate in this clinical study);
• use of aerosols, creams, suppositories and other agents containing spermicides;
• use of intrauterine device by female partner.

Exclusion Criteria

1. History of allergies, including at least one episode of allergy to medications.

2. Chronic diseases of the cardiovascular, bronchopulmonary, neuroendocrine systems, ENT, as well as diseases of the gastrointestinal tract, liver, kidneys, blood, skin.

3. Hypolactasia (lactose intolerance, lactase deficiency) or glucose-galatose malabsorption in medical history.

4. Chronic eye diseases except for myopia, hypermetropia and astigmatism of mild and moderate severity.

5. Surgeries on the gastrointestinal tract (except for appendectomy done more than 1 year before screening).

6. Regular administration or use (including externally) of hormonal agent for more than 1 week less than 45 days before screening

7. Regular administration of medicinal products less than 4 weeks before screening.

8. Use of medicinal products that have a pronounced effect on liver function or hemodynamics (barbiturates, omeprazole, cimetidine, etc.) less than 30 days before screening.

9. Positive test for narcotics and psychotropic products.

10. Blood pressure after resting in supine position for at least 5 minutes above 130 mm Hg (systolic blood pressure) and 90 mm Hg (diastolic blood pressure) or below 110 mm Hg (systolic blood pressure) and 60 mm Hg (diastolic blood pressure).

11. Heart rate (according to ECG) after resting in supine position for at least 5 minutes above 90 bpm or below 60 bpm.

12. Blood donation (450 mL of blood or plasma and more) less than 3 months before the screening.

13. Acute infectious diseases less than 4 weeks before screening.

14. Administration of more than 10 units of alcohol per week (1 unit of alcohol is equivalent to 500 mL of beer, 200 mL of wine or 50 mL of a spirit) or history of alcoholism, drug abuse, substance abuse.

15. Mental diseases.

16. Smoking for three months before screening.

17. Participation in any clinical study less than 3 months before screening.

18. Planned conception or sperm donation during the study after the administration of the investigational product or within 3 months after the last administration of the product.

19. Positive pregnancy test for women.

20. Breastfeeding period.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Nearmedic Plus LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Clinical hospital at the Yaroslavl station of the Open Joint Stock Company Russian Railways

Yaroslavl, , Russia

Countries

Russia

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

PBTZ169-Z00-C01-3

Identifier Type: -

Identifier Source: org_study_id